MedWatch

Analyst: Biden's insulin message won't negatively impact Novo Nordisk

The debate about prescription drug prices in the US is far from new, says Sydbank Analyst Søren Løntoft Hansen, pointing out that past years’ discounts on insulins haven’t stopped Novo Nordisk from booking record-breaking results.

Photo: Novo Nordisk / PR

On Tuesday, President of the United States Joe Biden announced in his State of the Union Address that he would lower the cost of prescription drugs in the US.

He specifically mentioned that insulin manufacturers overprice their drugs in the country, which is pharmaceutical firm Novo Nordisk’s biggest market measured in sales.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs